| Zaker Hamid Rana, MD | |
|
850 W Baltimore St, Baltimore, MD 21201-1110 | |
| (410) 369-5200 | |
| Not Available |
| Full Name | Zaker Hamid Rana |
|---|---|
| Gender | Male |
| Speciality | Radiation Oncology |
| Experience | 9 Years |
| Location | 850 W Baltimore St, Baltimore, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104213578 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0001X | Radiology - Radiation Oncology | D90305 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Maryland Medical Center | Baltimore, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Maryland Proton Treatment Center, Llc | 5597070524 | 18 |
| University Of Maryland Radiation Oncology Associates Pa | 6406845544 | 29 |
News Archive
The Senate Appropriations Committee Thursday unanimously voted to approve a $59 billion war funding measure that includes "more than $5 billion to replenish disaster aid accounts, as well as funding for Haitian earthquake relief," the Associated Press reports (Taylor, 5/13).
MedQuist Holdings Inc., a leading provider of integrated clinical documentation solutions for the U.S. healthcare system, today announced that it has extended the expiration date for its exchange offer for all issued and outstanding shares of MedQuist Inc. common stock until 5:00 p.m., New York City time, on Friday, March 11, 2011, unless further extended or earlier terminated.
Advanced BioMedical Technologies Inc. announced that the Company's subsidiary, Shenzhen Changhua Biomedical Engineering Co., Ltd., has signed a cooperative agreement with The First Affiliated Hospital of Guangdong Pharmaceutical University ("GDPU Hospital") in Guangzhou. Under this cooperative agreement, both parties will join efforts in conducting research and animal tests on Cranio-Maxillofacial Fracture Treatment and Craniofacial Reconstruction utilizing ABT-CHANGHUA's novel patented PA (Polyamide) bio-absorbable material.
Aeterna Zentaris Inc. today announced that an article on final data for the Phase 1 portion of the ongoing Phase 1/2 trial in prostate cancer with zoptarelin doxorubicin (formerly AEZS-108), a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin, has been published in the December issue of Clinical Cancer Research.
Fractured teeth, neck injuries and abrasions in the mouth, also known as sports-related dental injuries, are ever present among athletes.
› Verified 7 days ago
| Entity Name | University Of Maryland Radiation Oncology Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780637272 PECOS PAC ID: 6406845544 Enrollment ID: O20040512000493 |
News Archive
The Senate Appropriations Committee Thursday unanimously voted to approve a $59 billion war funding measure that includes "more than $5 billion to replenish disaster aid accounts, as well as funding for Haitian earthquake relief," the Associated Press reports (Taylor, 5/13).
MedQuist Holdings Inc., a leading provider of integrated clinical documentation solutions for the U.S. healthcare system, today announced that it has extended the expiration date for its exchange offer for all issued and outstanding shares of MedQuist Inc. common stock until 5:00 p.m., New York City time, on Friday, March 11, 2011, unless further extended or earlier terminated.
Advanced BioMedical Technologies Inc. announced that the Company's subsidiary, Shenzhen Changhua Biomedical Engineering Co., Ltd., has signed a cooperative agreement with The First Affiliated Hospital of Guangdong Pharmaceutical University ("GDPU Hospital") in Guangzhou. Under this cooperative agreement, both parties will join efforts in conducting research and animal tests on Cranio-Maxillofacial Fracture Treatment and Craniofacial Reconstruction utilizing ABT-CHANGHUA's novel patented PA (Polyamide) bio-absorbable material.
Aeterna Zentaris Inc. today announced that an article on final data for the Phase 1 portion of the ongoing Phase 1/2 trial in prostate cancer with zoptarelin doxorubicin (formerly AEZS-108), a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin, has been published in the December issue of Clinical Cancer Research.
Fractured teeth, neck injuries and abrasions in the mouth, also known as sports-related dental injuries, are ever present among athletes.
› Verified 7 days ago
| Entity Name | Maryland Proton Treatment Center, Llc |
|---|---|
| Entity Type | Part B Supplier - Radiation Therapy Center |
| Entity Identifiers | NPI Number: 1255742375 PECOS PAC ID: 5597070524 Enrollment ID: O20150819008188 |
News Archive
The Senate Appropriations Committee Thursday unanimously voted to approve a $59 billion war funding measure that includes "more than $5 billion to replenish disaster aid accounts, as well as funding for Haitian earthquake relief," the Associated Press reports (Taylor, 5/13).
MedQuist Holdings Inc., a leading provider of integrated clinical documentation solutions for the U.S. healthcare system, today announced that it has extended the expiration date for its exchange offer for all issued and outstanding shares of MedQuist Inc. common stock until 5:00 p.m., New York City time, on Friday, March 11, 2011, unless further extended or earlier terminated.
Advanced BioMedical Technologies Inc. announced that the Company's subsidiary, Shenzhen Changhua Biomedical Engineering Co., Ltd., has signed a cooperative agreement with The First Affiliated Hospital of Guangdong Pharmaceutical University ("GDPU Hospital") in Guangzhou. Under this cooperative agreement, both parties will join efforts in conducting research and animal tests on Cranio-Maxillofacial Fracture Treatment and Craniofacial Reconstruction utilizing ABT-CHANGHUA's novel patented PA (Polyamide) bio-absorbable material.
Aeterna Zentaris Inc. today announced that an article on final data for the Phase 1 portion of the ongoing Phase 1/2 trial in prostate cancer with zoptarelin doxorubicin (formerly AEZS-108), a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin, has been published in the December issue of Clinical Cancer Research.
Fractured teeth, neck injuries and abrasions in the mouth, also known as sports-related dental injuries, are ever present among athletes.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Zaker Hamid Rana, MD 850 W Baltimore St, Baltimore, MD 21201-1110 Ph: (410) 369-5200 | Zaker Hamid Rana, MD 850 W Baltimore St, Baltimore, MD 21201-1110 Ph: (410) 369-5200 |
News Archive
The Senate Appropriations Committee Thursday unanimously voted to approve a $59 billion war funding measure that includes "more than $5 billion to replenish disaster aid accounts, as well as funding for Haitian earthquake relief," the Associated Press reports (Taylor, 5/13).
MedQuist Holdings Inc., a leading provider of integrated clinical documentation solutions for the U.S. healthcare system, today announced that it has extended the expiration date for its exchange offer for all issued and outstanding shares of MedQuist Inc. common stock until 5:00 p.m., New York City time, on Friday, March 11, 2011, unless further extended or earlier terminated.
Advanced BioMedical Technologies Inc. announced that the Company's subsidiary, Shenzhen Changhua Biomedical Engineering Co., Ltd., has signed a cooperative agreement with The First Affiliated Hospital of Guangdong Pharmaceutical University ("GDPU Hospital") in Guangzhou. Under this cooperative agreement, both parties will join efforts in conducting research and animal tests on Cranio-Maxillofacial Fracture Treatment and Craniofacial Reconstruction utilizing ABT-CHANGHUA's novel patented PA (Polyamide) bio-absorbable material.
Aeterna Zentaris Inc. today announced that an article on final data for the Phase 1 portion of the ongoing Phase 1/2 trial in prostate cancer with zoptarelin doxorubicin (formerly AEZS-108), a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin, has been published in the December issue of Clinical Cancer Research.
Fractured teeth, neck injuries and abrasions in the mouth, also known as sports-related dental injuries, are ever present among athletes.
› Verified 7 days ago
Dr. Barun Aryal, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 3001 S Hanover St, Dept Of Internal Medicine, Baltimore, MD 21225 Phone: 410-350-3565 Fax: 410-354-0186 | |
Imran Ahmed, D.O Radiology Medicare: Accepting Medicare Assignments Practice Location: 22 S Greene St, Dept Of Radiology, Baltimore, MD 21201 Phone: 410-328-3477 | |
Michael Goldman, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 301 Saint Paul Pl, Radiology Dept, Baltimore, MD 21202 Phone: 410-332-9266 Fax: 410-545-4255 | |
Dr. Jeffrey R. Galvin, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 22 S Greene St, Dept Of Radiology, Baltimore, MD 21201 Phone: 410-328-3477 | |
Martin Auster, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 4940 Eastern Ave, Baltimore, MD 21224 Phone: 410-550-0214 | |
Amy K Pepperney, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 7253 Ambassador Rd, Baltimore, MD 21244 Phone: 443-436-1151 Fax: 443-436-1256 | |
Carolyn Kwon, Radiology Medicare: May Accept Medicare Assignments Practice Location: 4940 Eastern Ave, Baltimore, MD 21224 Phone: 410-550-0100 |